|
KMID : 0811720160200010063
|
|
Korean Journal of Physiology & Pharmacology
2016 Volume.20 No. 1 p.63 ~ p.67
|
|
|
Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study
|
|
Yi Hyeon-Gyu
Yahng Seung-Ah
Kim In-Ho
Lee Je-Hwan
Min Chang-Ki
Kim Jun-Hyung
Kim Chul-Soo
Song Sun-U.
|
|
|
Abstract
|
|
|
|
Severe graft-versus-host disease (GVHD) is an often lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). The safety of clinicalgrade mesenchymal stem cells (MSCs) has been validated, but mixed results have been obtained due to heterogeneity of the MSCs. In this phase I study, the safety of bone marrow-derived homogeneous clonal MSCs (cMSCs) isolated by a new subfractionation culturing method was evaluated. cMSCs were produced in a GMP facility and intravenously administered to patients who had refractory GVHD to standard treatment resulting after allogeneic HSCT for hematologic malignancies. After administration of a single dose (1×106 cells/kg), 11 patients were evaluated for cMSC treatment safety and efficacy. During the trial, nine patients had 85 total adverse events and the rate of serious adverse events was 27.3% (3/11 patients). The only one adverse drug reaction related to cMSC administration was grade 2 myalgia in one patient. Treatment response was observed in four patients: one with acute GVHD (partial response) and three with chronic GVHD. The other chronic patients maintained stable disease during the observation period. This study demonstrates single cMSC infusion to have an acceptable safety profile and promising efficacy, suggesting that we can proceed with the next stage of the clinical trial.
|
|
|
KEYWORD
|
|
|
Bone marrow, Graft-versus-host disease, Hematopoietic stem cell transplantation, Mesenchymal stem cells
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|